Common fragile sites and cancer (Review)

International Journal of Oncology

Volumn 12, Issue 1, 1998, Pages 187-196

  Smith, David I ^a   Huang, Haojie ^a   Wang, Liang ^a  

^a MAYO CLINIC   (United States)

Author keywords

Fragile sites

Indexed keywords

DNA; ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN;

CANCER; CANCER SUSCEPTIBILITY; CHROMOSOMAL LOCALIZATION; CHROMOSOME FRAGILE SITE; DNA REPLICATION; DNA SEQUENCE; GENE DELETION; HUMAN; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; YEAST ARTIFICIAL CHROMOSOME; CHROMOSOME 3; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME FRAGILITY; COMPARATIVE STUDY; FEMALE; GENETICS; MALE; NEOPLASM;

ACID ANHYDRIDE HYDROLASES; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0031963434     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.1.187     Document Type: Review

References (85)

1. Berger R, Bloomfield CD and Sutherland GR: Human gene mapping 8: report on the committee on chromosome rearrangments in neoplasia and on fragile sites. Cytogenet Cell Genet 40: 490-535, 1983.
2. Sutherland GR and Hecht F: Fragile sites on chromosomes. In: Oxford University Monographs on Medical Genetics. No. 13. Oxford University Press, New York, 1985.
3. Sutherland GR: Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197: 265-266, 1977.
4. Sutherland GR, Parslow MI and Baker E: New classes of common fragile sites induced by 5-azacytidine and bromodeoxyuridine. Hum Genet 69: 233-237, 1985.
5. Glover TW, Berger C, Coyle-Morris H and Echo B: DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites. Hum Genet 67: 136-142, 1984.
6. Glover TW and Stein CK: Chromosomal breakage and recombination at common fragile sites. Hum Genet 43: 265-273, 1988.
7. Verkerk AJMH, Pieretti M, Sutclife JSA, Fu Y-H, Kulh DPA, Pizuti A, Reiner O, Richards S, Victoria MF, Zhang F, et al: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65: 905-914, 1991.
8. Yu S, Pritchard M, Kremer E, Lynch M, Nancarrow J, Baker E, Holman K, Mulley JC, Warren ST, Schlessinger D, et al: Fragile X syndrome characterized by an unstable region of DNA. Science 252: 1179-1182, 1991.
9. Fu Y-H, Kuhl DP, Pizzuti A, Pieretti M, Sutclife JS, Richards S, Verkerk AJMH, Holden JJA, Fenick RG Jr, Warren ST, Oostra BA, Nelson DA and Caskey CT: Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67: 1047-1058, 1991.
10. Pieretti M, Zhang F, Fu Y-H, Warren ST, Oostra BA, Caskey CT and Nelson DL: Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66: 817-822, 1991.
11. Knight SJL, Flannery AV, Hirst MC, Campbell L, Middleton-Price HR, Barnicoat A, Pembrey ME, Holland J, Oostra BA, Bobrow M and Davies KE: Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental 4 retardation. Cell 74: 127-135, 1993.
12. Ritchie RJ, Knight SHL, Hirst MC, Grewal PK, Bobrow M, Cross GS and Davies KE: The cloning of FRAXF: trinucleotide repeat expansion and methylation at a third fragile site in distal Xqter. Hum Mol Genet 3: 2115-2121, 1994.
13. Jones C, Slijepcevic P, Marsh S, Baker E, Langdon WY, Richards RI and Tunnacliffe A: Physical linkage of the fragile site, FRA11B, and a Jacobsen syndrome chromosome deletion breakpoint in 11q23.3. Hum Genet 12: 2123-2130, 1994.
14. Nancarrow JK, Kremer E, Holman K, Eyre H, Dogget NA, Le Paslier D, Callen DF, Sutherland GR and Richards RI: Implications of FRA16A structure for the mechanism of fragile site genesis. Science 264: 1938-1941, 1994.
15. Wang YH, Gellibolian R, Simizu M, Wells RD and Griffith J: Long CCG triplet repeat blocks exclude nucleosomes: a possible mechanism for the nature of fragile sites in chromosomes. J Mol Biol 263: 511-516, 1996.
16. Yu S, Mangelsdorf M, Hewett D, Hobson L, Baker E, Eyre HJ, Lapsys N, le Paslier D, Doggett NA, Sutherland GR and Richards RI: Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell 88: 367-374, 1997.
17. Yunis JJ and Soreng AL: Constitutive fragile sites and cancer. Science 226: 1199-1204, 1984.
18. Smeets DFCM, Scheres JMJC and Hustinx TWJ: The most common fragile site in man is 3p14. Hum Genet 72: 215-220, 1986.
19. Glover TW and Stein CK: Induction of sister chromatid exchanges at common fragile sites. Am J Hum Genet 41: 882-890, 1987.
20. Wang N-D, Testa JR and Smith DI: Determination of the specificity of aphidicolin-induced breakage of the human 3p14.2 fragile site. Genomics 17: 341-347, 1993.
21. Rassool FV, McKeithan TW, Neilly ME, van Meele E, Espinosa R and LeBeau MM: Preferential integration of marker DNA into the chromosomal fragile site at 3p14.2: a novel approach to cloning fragile sites. Proc Natl Acad Sci USA 88: 6657-6661, 1991.
22. Coquelle A, Pipiras E, Toledo F, Buttin G and Debatisse M: Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89: 215-225, 1997.
23. LeBeau MM and Rowley JD: Heritable fragile sites and cancer. Nature 308: 607-608, 1984.
24. Sutherland GR and Ledbetter DH: Report of the committee on cytogenetic markers. Human Gene Mapping 10. Cytogenet Cell Genet 51: 452-458, 1989.
25. Daniel A: Clinical implications and classification of the constitutive fragile sites. Am J Hum Genet 23: 419-427, 1986.
26. Gustavson KH, Bloomquist G and Holmgren G: Prevalence of fragile-X syndrome in mentally retarded children in a Swedish country. Am J Med Genet 23: 581-587, 1986.
27. Webb TP, Bundey AI, Thake J and Todd J: Population incidence and segregtion ratios in Martin-Bell syndrome. Am J Med Genet 23: 573-580, 1986.
28. Caskey CT, Pizzuti A, Fu Y-H, Fenwick RG Jr and Nelson DL: Triplet repeat mutations in human disease. Science 256: 784-789, 1992.
29. Yunis JJ, Soreng AL and Bowe A: Fragile sites are targets for diverse mutagens and carcinogens. Oncogene 1: 59-69, 1987.
30. Hirsch B: Sister chromatid exchanges are preferentially induced at expressed and non-expressed common fragile sites. Hum Genet 87: 302-306, 1991.
31. Hecht F and Sutherland GR: Fragile sites and cancer breakpoints. Cancer Genet Cytogenet 12: 179-181, 1984.
32. Parrish JE, Oostra BA, Verkerk AJMH, Richards CS, Reynolds J, Spikes AS, Shaffer LG and Nelson DL: Isolation of a GCC repeat showing expansion in FRAXF, a fragile site distal to FRAXA and FRAXE. Nat Genet 8: 236-242, 1994.
33. Willems PJ: Dynamic mutations hit double figures. Nat Genet 8: 213-215, 1994.
34. Lindblad K, Zander C, Schalling M and Hudson T: Growing triplet repeats. Nat Genet 7: 124, 1994.
35. Hecht F and Glover TW: Cancer chromosome breakpoints and fragile sites induced by aphidicolin. Cancer Genet Cytogenet 13: 185-188, 1984.
36. Naylor SL, Johnson BE, Minna JD and Sakaguchi AY: Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329: 451-454, 1987.
37. Brauch H, Johnson B, Hovis J, Yano T, Gazdar A, Pettengill OS, Graziano S, Sorenson GD, Poiesz BJ, Minna J, et al: Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Eng J Med 317: 1109-1113, 1987.
38. Zbar B, Brauch H, Talmadge C and Linehan M: Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327: 721-724, 1987.
39. Kovac G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, Klein G and Sumegi J: Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85: 1571-1575, 1988.
40. Shridhar R, Shridhar V, Wang X, Paradee W, Dugan M, Sarkar F, Wilke C, Glover TW, Vaitkevicius VK and Smith DI: Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res 56: 4347-4350, 1996.
41. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tasai S, Jacobs SC and Brown RS: Hereditary renal cell carcinoma associated with a ; chromosomal translation. N Engl J Med 301: 592-595, 1979.
42. Latil A, Cussenot O, Fournier G, Driouch K and Lidereau R: Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res 57: 1058-1062, 1997.
43. Dorion-Bonnet F, Mautalen S, Hostein I and Longy M: Allelic imbalance study of 16q in human primary breast carcinomas using microsatellite markers. Genes Chromosom Cancer 14: 171-181, 1995.
44. Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T and Hirohashi S: Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87: 6791-6794, 1990.
45. Sato T, Akiyama F, Sakamoto G, Kasumi F and Nakamura Y: Allelotype of human ovarian cancer. Cancer Res 51: 5118-5121, 1994.
46. Cooke IE, Shelling AN, Le Meuth VG, Charnock FML and Ganesan TS: Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosom Cancer 15: 223-233, 1996.
47. Saito S, Saito H, Koi S, Sagae S, Kudo R, Saito J, Noda K and Nakamura Y: Fine-scale deletion mapping of the distal long arm of chromosome 6 in 70 human ovarian cancers. Cancer Res 52: 5815-5817, 1992.
48. Queimado L, Seruca R, Costa-Pereira A and Castedo S: Identification of two distinct region of deletion at 6q in gastric carcinoma. Genes Chromosom Cancer 14: 28-34, 1995.
49. Zenklusen JC, Thompson JC, Tronscoso P, Kagan J and Conti CJ: Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res 54: 6370-6373, 1994.
50. Champeme M-H, Bieche I, Beuzelin M and Lidereau R: Loss of heterozygosity on 7q31 occurs early during breast tumorigenesis. Genes Chromosom Cancer 12: 304-306, 1995.
51. Hahn SA, Seymour AB, Hoque ATMS, Schutte M, de Costa LT, Redston MS, Caldas C, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE: Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res 55: 4670-4675, 1995.
52. Michaelis SC, Bardenheuer W, Lux A, Schramm A, Gockel A, Siebert R, Willers C, Schmidtke K, Todt B, van der Hout AH, Buys CHCLM, Heppel-Parton AC, Rabbitts PH, Ungar S, Smith D, LePaslier D, Cohen D, Opalka B and Schutte J: Characterization and chromosomal assignment of yeast artificial chromosomes containing human 3p13-p21-specific sequence tagged sites. Cancer Genet Cytogenet 81: 1-12, 1995.
53. Bardenheuer W, Michaelis S, Lux A, Vieten L, Brocker F, Julicher K, Willers C, Siebert R, Smith DI, van der Hout AH, Busy C, Schutte J and Opalka B: Construction of a consistent YAC contig for human chromosome region 3p14.1. Genome Res 6: 176-186, 1996.
54. Boldog FL, Gemmill RM, Wilke CM, Glover TW, Nilsson AS, Chandrasekharappa SC, Brown RS, Li FP and Drabkin HA: Positional cloning of the hereditary renal cell carcinoma t(3;8) chromosome translocation breakpoint. Proc Natl Acad Sci USA 90: 8509-8513, 1993.
55. Wilke CM, Guo SW, Hall BK, Boldog F, Gemmill RM, Chandrasekharappa SC, Barcroft CL, Drabkin HA and Glover TW: Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both fRA3B and the t(3;8) associated with hereditary renal cell carcinoma. Genomics 22: 319-326, 1994.
56. Paradee W, Wilke CM, Wang L, Shridhar R, Mullins CM, Hoge A, Glover TW and Smith DI: A 350 Kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints. Genomics 35: 87-93, 1996.
57. Rassool FV, LeBeau MM, Shen M-L, Neilly ME, Espinosa III R, Ong ST, Boldog F, Drabkin H, McCarroll R and McKeithan TW: Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2 Genomics 35: 109-117, 1996.
58. Wang L, Paradee W, Mullins C, Shridhar R, Rosati R, Wilke CM, Glover TW and Smith DI: Aphidicolin-induced FRA3B breakpoints cluster in two distinct regions. Genomics 41: 486-488, 1997.
59. Zimonjic DB, Druck T, Ohta M, Kastury K, Croce CM, Popescu NC and Huebner K: Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res 57: 1166-1170, 1997.
60. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI and Glover TW: FRA3B extends over a broad region and contains a spontaneous HPV16 viral integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 5: 187-195, 1996.
61. Lisitsyn NA, Lisitsina NM, Dalbagni G, Barker P, Sanchez CA, Gnarra J, Linehan WM, Reid BJ and Wigler MH: Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci USA 92: 151-155, 1995.
62. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J and Huebner K: Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 56: 978-983, 1996.
63. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprshvili Z, Mori M, McCue P, Durck T, Croce CM and Huebner K: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597, 1996.
64. 4A) assymetrical hydrolase: sequence similarity with histidine triad (HIT) family. Biochem J 312: 925-932, 1995.
65. Barnes LD, Garrison PN, Sprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M and Huebner K: Fhit, a putative tumor suppressor in humans is a dinucleoside 5′,5‴-P1,P3,Triphosphate hydrolase. Biochemistry 35: 11529-11535, 1996.
66. Negrini M, Moaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Croce CM: The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173-3179, 1996.
67. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM: The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996.
68. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K and Croce CM: FHIT gene alterations in head and neck and squamous cell carcinomas. Proc Natl Acad Sci USA 93: 9770-9775, 1996.
69. Druck T, Hadaczek P, Fu T-B, Ohta M, Siprashvili Z, Baffa R, Negrinin M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM and Huebner CM: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57: 504-512, 1997.
70. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JKV, Markowitz SD, Leach FS, Kinzler KW and Vogelstein B: Evaluation of the FHIT gene in colorectal cancers. Cancer Res 56: 2936-2939, 1996.
71. Boldog F, Bemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Waggoner B, Lundstrom R, Jacobson J, Mullokandov MR, Klinger H and Drabkin HA: Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 6: 193-203, 1997.
72. Van den Berg A, Diaajers TG, Kok K, Timmer T, van der Veen AY, Veldhuis PMJ, le Leij L, Gerhartz CD, Naylor SL, Smith DI and Buys CHCM: Normal FHIT transcripts in renal cell cancer and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chromosom Cancer 19: 1-8, 1997.
73. Wang L, Darling J, Zhang J-S, Qian C-P, Hartmann L, Conover C, Jenkins R and Smith DI: Frequent homozygous deletions in the FRA3B region in tumor cell lines still leave the FHIT exons intact Oncogene (In press).
74. Rao PN, Heerema NA and Palmer CG: Fragile sites induced by FUdR, caffeine, and aphidicolin. Their frequency, distribution and analysis. Hum Genet 78: 21-26, 1988.
75. Abruzzo MA, Pettay D, Mayer M and Jacobs PA: The effect of caffeine on fragile X expression. Hum Genet 73: 20-22, 1986.
76. Kuniyasu H, Yasui W, Yokozaki H, Akagi M, Kitahara K, Fujii K and Tahara E: Frequent loss of heterozygosity of the long arm of chromosome 7 is closely associated with progression of human gastric carcinomas. Int J Cancer 59: 597-600, 1994.
77. Zenklusen J, Weitzel J, Ball H and Conti C: Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. Oncogene 11: 359-363, 1995.
78. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN and Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55: 4114-4119, 1995.
79. Lail A, Cussenot O, Fournier G, Baron JC and Lidereau R: Loss of heterzygosity at 7q31 is a frequent and early event in prostate cancer. Cancer Res 55: 1058-1062, 1997.
80. n microsatellite D7S522 is the most commonly deleted region in human primary breast cancer. Proc Natl Acad Sci USA 91: 12155-12158, 1994.
81. Koike M, Takeuchi S, Yokota J, Park S, Hatta Y, Miller CW, Tsuruoka N and Koeffler HP: Frequent loss of heterozygosity in the region of the D7S523 locus in advanced ovarian cancer. Genes Chromosom Cancer 19: 1-5, 1997.
82. Jones NJ, Stewart SA and Thompson LH: Biochemical and genetic analysis of the Chinese hamster mutants irs1 and irs2 and their comparison to cultured ataxia telangiectasia cells. Mutagenesis 5: 15-23, 1990.
83. Ledbetter SA, Garcia-Heras J and Ledbetter DH: PCR-karyotype of human chromosomes in somatic cell hybrids. Genomics 8: 614-622, 1990.
84. Bouffard GG, Idol JR, Braden VV, Iyer LM, Cunningham AF, Weintraub LA, Touchman JW, Mohr-Tidwell RM, Peluso DC, Fulton RS, Ueltzen MS, Weissenbach J, Magness CL and Green ED: A physical map of human chromosome 7: an integrated YAC contig map with average spacing of 79 Kb. Genome Res 7: 673-692, 1997.
85. Huang H, Qian C, Jenkins RB and Smith DI: FISH mapping of YAC clones at human chromosomal band 7q31.2: identification of YACs spanning FRA7G within the common region of LOH in breast and prostate cancer. Genes Chromosm Cancer (In press).